AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in mental health conditions ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Bristol Surges AbbVie’s setback was viewed as a victory for Bristol Myers Squibb Co., which in late September gained US approval for the first new type of schizophrenia drug in seven decades.

The recent approval of Karuna's schizophrenia drug Cobenfy stands ... with ample time to bring forward the next generation of new drugs. Several of Bristol's currently marketed drugs are biologics ...

AbbVie said on Monday that an experimental schizophrenia drug it gained through an $8.7 billion deal for Cerevel Therapeutics failed two mid-stage studies, sending the drugmaker's shares plunging 12.5 ...

"Severe neutropenia occurs in a small percentage of patients taking clozapine; however, neutropenia is associated with an ...